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Objectives: The identification of early phase interstitial changes may influence the under-
standing of idiopathic interstitial pneumonitis. This study aimed to clarify its radiological
patterns and the association with smoking.
Methods: The subjects underwent low-dose computed tomography to screen lung cancer. The
selected subjects with interstitial changes were monitored for the precise morphology of inter-
stitial changes using a high-resolution computed tomography (HRCT) scan. The subjects were
classified into normal and abnormal HRCT subjects. The radiological findings on the HRCT scan,
serum Klebs von der Lungen-6 (KL-6), surfactant protein (SP)-A, SP-D, pulmonary function, and
computed tomography (CT) scores were analyzed. Abnormal HRCT subjects were classified
based on the radiological patterns, and were followed-up over a 4-year period.
Results: HRCT abnormalities suggesting interstitial changes were identified in 80 of 3079
subjects. Seven subjects with honeycombing and 14 with combined pulmonary fibrosis and
emphysema (CPFE) were identified. The frequencies of sex (male) and smoking in the subjects
with honeycombing was higher than that of other patterns. The smoking history and the levels
of serum KL-6, SP-A, and SP-D in abnormal HRCT subjects were significantly higher than those
in normal HRCT subjects. Thirty-two of 73 abnormal HRCT subjects showed a progression of the
CT scores in a chest HRCT over a 4-year period. Eighteen abnormal HRCT current smokers were
included in the progression of CT scores.
Conclusions: HRCT patterns, excluding interlobular septal thickening, show the progression of
CT scores. Smokers with CT abnormalities may have a tendency to demonstrate worsening
interstitial changes.
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The radiological patterns of interstitial change 1713Introduction and the same kinds of agricultural activities. During theMany hospitals in Japan have begun screening using low-
dose chest computed tomography (CT) to detect lung
cancer. Various abnormalities, such as a low attenuation
area,1 bronchial wall thickness,2 bronchiectasis, and
fibrosis, are often identified in addition to cancerous or
benign nodules using a CT scan. For the detection of
interstitial lung disease (ILD), high-resolution computed
tomography (HRCT) is clearly more sensitive than a chest X-
ray.3 The widespread use and improved understanding of
the value of HRCT scans in the evaluation of these diseases
has led to an increased understanding of the extent and
severity of the lesions that are commonly observed.4,5 A
quantitative method using digital data as well as a visual
assessment of the scan is currently available for the anal-
ysis of CT images.6e8
Patients with idiopathic pulmonary fibrosis (IPF) are
usually more than 50 years of age at the time of onset.9 The
natural history of IPF is poorly understood because these
patients are generally identified at an advanced disease
stage. An early stage of asymptomatic ILD has been previ-
ously reported by Marshall,10 Hodgson,11 Bitterman,12 and
Rosas.13 In the early stages of ILD according to the HRCT
findings, the degree of parenchymal infiltration may be so
slight that it presents without detectable abnormalities in
the chest radiographs or pulmonary function tests.9 The
pulmonary function test findings tend to be normal in
asymptomatic familial ILD patients. Lung biopsies from
early ILD patients with familial IPF have demonstrated
various histological subtypes, including usual interstitial
pneumonia (UIP), hypersensitivity pneumonia, non-specific
interstitial pneumonia (NSIP), and cellular interstitial and
organizing pneumonia.13
The current study was performed to assess the ability of
HRCT to clarify the radiological pattern of early phase
interstitial changes and to estimate the association
between HRCT patterns and smoking using clinical param-
eters, pulmonary function tests, and the chest HRCT scans.
The subjects, who were detected to have interstitial
change by a chest HRCT scan, were followed-up by chest CT
for a period of approximately 4 years.
Patients and methods
The research protocol, including the laboratory data, the
presentation of HRCT, and the pulmonary function test, was
approved by the human ethics committee of Azumi General
Hospital. All subjects gave informed consent to check each
low-dose CT scan and collect clinical records. All selected
subjects for further examination gave their informed
consent at the time of explanation for a chest CT scan.
Subjects
The enrolled subjects were from the rural population of the
area in the Nagano Prefecture. The Nagano Prefecture is
located approximately 700 m above sea level, and the air in
this area is cleaner than in other urban prefectures in
Japan.14 People in this region have been generally living in
the same place and continuing to work in the same industrieshealth screening program for the detection of lung cancer as
a population strategy (January 1, 2004 to December 31,
2004), the enrolled subjects, who were concerned about
their health, received a general health check including
a low-dose chest CT scan. The subjects filled out a ques-
tionnaire about their lifestyle, habitual drugs, respiratory
symptoms, smoking history, past history, and demographic
data according to the modified American Thoracic Society
questionnaire.15 The questions about respiratory symptoms
were related to cough, sputum, and shortness of breath. The
type and amount of exertion required to precipitate short-
ness of breath were assessed using the Borg scale and the
British Medical Reseach Council dyspnea scale.
Low-dose CT scan
Each subject first underwent a multi-detector low-dose CT
scan (Toshiba Asteion Multi, Tokyo, Japan) (25mA, 120 kV, 5-
mm section thickness, 0.75 s of rotation). All CT images were
viewed in the cine-mode format on a computer workstation
by a radiologist (S.S.) and a pulmonologist (K.T.) with 45 and
15 years of experience, respectively, and were displayed
under three display conditions to allow adequate examina-
tion of the lungs, hilar bronchi, andmediastinum (width 1000
Hounsfield units (HU), level 700 HU; width 1500 HU, level
550 HU; width 300 HU, level 20 HU, respectively). The
definition for recruitment of further examinations is the
existence of interstitial changes present on the CT scans. To
prevent overlooking any false negative subjects, the normal
subjects with low-dose CT scan were examined using past
low-dose CT after the initial low-dose screening.
Further examination criteria
The subjects with interstitial changes on the low-dose CT
scan were recruited by mail to undergo further examina-
tions to check for additional clinical findings (clubbed
finger, fine crackles), and also to measure such factors as
serum lactate dehydrogenase (LDH) (normal range,
114e220 IU/l), Klebs von der Lungen-6 (KL-6) (normal
range, <500 U/l), surfactant protein (SP)-A (normal range,
<43.8 ng/ml), SP-D (normal range, <110 ng/ml), resting
alveolar-arterial oxygen difference (AaDO2), and the 6-min
walk test. The patients underwent a chest HRCT scan 1
month after the initial low-dose CT scans to rule out aspi-
ration pneumonia or pneumonia, and also to carry out
pulmonary function tests.
HRCT scan
The HRCT scan parameters were 150 mA, 120 kVp, 5-mm
section thickness, and 0.75 s of rotation. Contiguous 5-mm
sections for the whole lung and thin-section images (1 mm
collimation) were used to cover the interstitial changes in
question while the patient was in the supine and prone
positions. The interstitial changes were classified by S.S. and
K.T. as follows: honeycombing, interlobular septal thick-
ening (IST), ground glass opacity (GGO), ill-defined sub-
pleural line (IDS), and combined pulmonary fibrosis and
emphysema (CPFE).16 When the patient was in the prone
1714 K. Tsushima et al.position, the same slice that was takenwhen the patient was
in the supine position showed no evidence of any abnor-
mality, and individuals with an abnormality on the low-dose
CT scans were reclassified as having normal HRCT findings.
When HRCT findings coexisted of categories in each subject,
we categorized these HRCT findings into a single category
based on the expansion of main HRCT patterns.
The severity of the interstitial changes was subjectively
scored using themodified scoringmethod of Kazerooni for six
slices obtained at full inspiration.17 The percentage of the
lung with interstitial changes was determined using the
following five-point scale: CTscore 1, 0< interstitial changes
<5% involvement; 2, 5%  interstitial changes <25%; 3,
25% interstitial changes<50%; 4, 50% interstitial changes
<75%; and 5, 75%. The maximum CT score is 30. The
quantitation of CTscorewas independentlymeasured by two
pulmonologists (K.T. and S.Y.).
The subjects who were still actively smoking were
counseled and strongly urged to stop smoking based on the
chest HRCT findings, and the smoking history of these
subjects was also carefully examined. The subjects with
detectable abnormalities in the chest HRCT were followed
by a CT scan approximately 4 years later. The baseline and
follow-up CT scans were independently read by two physi-
cians using a previously described quantitative scale.17 Any
discrepant readings of the HRCT findings and CT scores
were reviewed again by both physicians together until
a consensus was obtained.
Pulmonary function test
The pulmonary function test was performed using the
routine method.18 The vital capacity (VC), forced vital
capacity (FVC), and maximal mid-expiratory flow (MMF)
were measured by a Spiroshift SP-700 (Fukuda Denshi,
Tokyo, Japan). The percent MMF was calculated, and the
peak expiratory flow rate (PEFR) and flow rate, at 50% and
25% of the forced vital capacity (V50, V25, respectively),
were calculated from the maximum expiratory flow-volume
curve. The V50/V25 and V25/height (V25/HT) were also
calculated. The functional residual capacity (FRC) with the
helium dilution method and the diffusing capacity for
carbon monoxide (DLco) were measured by a Chestac-55V
(Chest Co., Tokyo, Japan). The ratio of each specific piece
of data was calculated according to the prediction equation
of the Japanese Society of Chest Disease.
6-Minute walk test
The subjects were instructed to walk at their own pace from
end to end while attempting to cover as much distance as
possible in the 6 min allotted. A research assistant timed the
walk and recorded the distance traveled, the Borg scales for
dyspnea and leg fatigue, and the pulse rate for each minute
of walking that was completed. The saturation difference
was calculated by the resting oxygen saturation (SpO2)minus
the lowest SpO2 during the 6-min walk test.
Statistical analysis
The differences in sex, age, smoking history, and pulmonary
function variables among subjects were assessed with theinterstitial changes. Data for continuous variables are
shown as the mean  standard deviation (SD). Student’s t-
test was used to assess the differences between two groups
and to test for any differences between subjects with and
without interstitial changes. The KruskaleWallis test was
used to measure the differences among groups. Pearson’s
chi-square test was performed to test for any differences in
the distribution of these categorical variables among each
group. A p-value of less than 0.05 was considered to be
statistically significant.
Results
Low-dose chest CT scan included false-positive
interstitial changes
The mean age of the enrolled subjects was 57.2  9.8 years
of age. The number of never, former, and current smokers
were 1478 (48.0%), 587 (19.1%), and 1014 (32.9%), respec-
tively. The numbers of male and female smokers were 1426
(89.1%) and 175 (10.9%), respectively. The mean pack-year
of former and current smokers was 20.7 and 29.0, respec-
tively. One hundred sixty-eight of 3079 subjects showed
interstitial changes on the low-dose CT scans. None of the
screened individuals had been previously detected to have
interstitial change prior to this study. No interstitial
changes were found in any normal subjects using the past
low-dose CT findings after selecting subjects with intersti-
tial changes based on the initial low-dose CT findings.
Chest HRCT scan could detect interstitial change
more accurately
One hundred and fifty of 168 subjects with an abnormality on
the low-dose CT scans participated in the further study.
Eighteen subjects did not give their consent for further
examination. After performing HRCT scans, the 150 subjects
were divided into 70 normal and 80 abnormal HRCTsubjects.
Twenty-six subjects with abnormal findings in a low-dose CT
scan were reclassified as having normal findings based on the
findings of a supine HRCT scan. Forty-four subjects with
abnormalities shown by HRCT scans when the patient was in
the supine position could be reclassified into normal findings
following chest HRCT scans in the prone position. Fifty-six
abnormal HRCT subjects (3 female subjects) were current or
former smokers. Two subjects showed interstitial change
involving more than 25% of the lung, 30 involved 5e25%, and
48 involved less than 5% on the chest HRCTscans. As shown in
Fig. 1, the HRCT findings when the patient was in the prone
position can be utilized for more precise detection of inter-
stitial changes than the HRCT scan taken when the patient is
in the supine position. Three coexisting patterns with ISTand
IDS, two with GGO and IST, and two honeycombing and IST
patterns were categorized into the IST, GGO, and honey-
combing patterns, respectively.
Smoking history was correlated with an
abnormality in the HRCT scans
As shown in Table 1, normal subject included 70 normal
HRCT subjects and 2811 normal subjects without interstitial
Figure 1 Representative abnormal high-resolution computed tomography (HRCT) images (A, D) and thin-slice HRCT images (B, C,
E, F) from two subjects. (A) shows mild interlobular septal thickening in a 50-year-old male smoker. (B) shows interlobular septal
thickening at the thin-slice image when the patient is in the supine position. (C) shows subpleural fibrosis in the thin-slice image
when the subject is in the prone position. This patient was classified as having interlobular septal thickening. (D) shows a mild ill-
defined opacity in a 71-year-old female non-smoking subject. (E) shows ill-defined opacity in the thin-slice image when the patient
is in the supine position. (F) shows interlobular septal thickening in the thin-slice image when the subject is in the prone position.
This patient was classified into ill-defined opacity.
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significantly older than those subjects with normal findings.
Eighteen subjects and one subject were scored as grades 1
and 2 on the British Medical Research Council dyspnea
scale, respectively. Two of these 4 subjects with fine
crackles and a clubbed finger showed interstitial changes
involving more than 25% of the lung. Twenty-eight abnormal
HRCT subjects (35%) had been exposed to occupational dust
or metal in the past.
Serum SP-A was sensitive to detect interstitial
change
As shown in Fig. 2, the subjects with abnormal HRCT
findings showed significantly higher serum KL-6, SP-A, and
SP-D levels in comparison to the normal HRCT subjects.
Abnormal levels of serum KL-6, SP-A, and SP-D were seen
in 14, 51, and 18 subjects with abnormal HRCT findings,
and 0, 29, and 1 normal HRCT subjects, respectively. The
identification of interstitial changes using the combination
between KL-6 and/or SP-A, SP-A and/or SP-D, and KL-6
and/or SP-D findings demonstrated a sensitivity of 64% and
a specificity of 64%, a sensitivity of 70% and a specificity of
64%, and a sensitivity of 33% and a specificity of 100%,
respectively. The serum SP-A level correlated with thepatient’s pack-year smoking history (r Z 0.32,
p < 0.0001).
Abnormal HRCT smoker showed significant
differences in the serum KL-6, SP-A, and SP-D
levels and in pulmonary functional data in
comparison to normal HRCT smoker
The mean chest CT score in the abnormal HRCT subjects
was 2.95  2.0. As shown in Table 2, the normal and
abnormal HRCT subjects were divided into non-smoker and
current or former smokers (smoker). The serum KL-6, SP-A
and SP-D levels were significantly higher in the abnormal
HRCT smoker in comparison to the normal HRCT smoker.
One subject with abnormal HRCT findings showed
a decreased VC of less than 80% and 6 showed a DLco of less
than 80%. No subjects fulfilled the criteria for respiratory
failure of less than 60 torr when in room air. Nine and 4
subjects showed lower abnormal levels than the standard
data of the FEV1/FVC and the DLco/alveolar volume (VA),
respectively. The FEV1/FVC and DLco/VA in abnormal HRCT
smoker was significantly lower in comparison with the
normal HRCT smoker. There were no differences in the 6-
min walk data between the abnormal HRCT smoker and the
normal HRCT smoker.
Table 1 Characteristics of normal and abnormal subjects clarified by low-dose CT scan and HRCT scan.
(A) Normal subject
(n Z 2981)
(B) Abnormal subject
(n Z 80)
P value
(A) vs. (B)
Age (years) 53.8  10.3 61.7  9.4 <0.0001
Sex, M/F 1738/1243 59/21 0.002
Smoking history
No. of subjects (%) 1531 (51.4) 56 (70.0) <0.0001
Current smokers (%) 969 (32.5) 36 (45.0) 0.014
Pack-year 29.7  9.9 46.0  19.3 <0.0001
Former smokers (%) 562 (18.9) 20 (25.0) 0.110
Pack-year 20.5  12.5 43.7  25.9 <0.0001
Never smokers (%) 1450 (48.6) 24 (30.0) 0.001
Symptoms e no. of
subjects (%)
Chronic cough 428(14.4) 10 (12.5) 0.393
Chronic sputum 532 (17.8) 18 (22.5) 0.177
Shortness of breath 8 (2.7) 12 (14.8) <0.0001
Physical examinations
-no. (%)
Fine crackles 0 (0) 21 (26.3) <0.0001
Fine crackles＋clubbed finger 0 (0) 4 (5.0) <0.0001
Data are the mean  SD. Categorical data (sex, smoking history e number of subjects, symptoms e cough, and sputum) were analyzed
by chi-square test. no, number; M, male; F, female.
Figure 2 The serum KL-6, SP-A, and SP-D levels indicated a significant increase in subjects with abnormal HRCT findings. The
plots show all data points that lie outside the 5th and 95th percentiles as symbols. (A) There were no significant differences in the
serum LDH levels between normal HRCT subjects and abnormal HRCT subjects (pZ 0.091). (B) The serum KL-6 levels in abnormal
HRCT subjects were significantly higher in comparison to those in normal HRCT subjects (p Z 0.002). (C) The serum SP-A levels in
the abnormal HRCT subjects were significantly higher than those in the normal HRCT subjects (p Z 0.004). (D) The serum SP-D
levels in the abnormal HRCT subjects were significantly higher than those in the normal HRCT subjects (p < 0.0001).
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Table 2 HRCT subjects classified by smoking history.
Abnormal HRCT (n) Normal HRCT (n) (A)vs(C)/(B)vs(D)
(A) Non-smoker
(24)
(B) Smoker
(56)
(C) Non-smoker
(20)
(D) Smoker
(50)
Age (years) 62.2  9.0 61.6  9.6 61  8.4 53.8  10 0.65/<0.0001
Sex, M/F 6/18 53/3* 10/10 48/2 0.060/0.34
Respiratory symptoms 13 41 13 24 0.47/0.0078
Pack-year 0 45.2  22 0 28.8  18 e/<0.0001
Fine crackles 3 18* 0 0 0.15/<0.0001
Fine crackles and
clubbed finger
0 4 0 0 1.00/0.074
KL-6 (U/mL) 350  463 473  647 265  98 229  77 0.44/0.011
SP-A (ng/mL) 44.2  18 57.1  23* 38.0  15.3 46.5  22 0.23/0.020
SP-D (ng/mL) 74.8  67 82.3  59 39.5  22 46.1  25 0.034/0.0001
Pulmonary function tests
VC predicted (%) 116  13.4 113  14.5 112  13.1 112  12.6 0.38/0.78
FEV1/FVC (%) 83.9  3.6 76.8  9.6* 83.4  5.5 82.9  7.2 0.73/0.0004
FEV1 predicted (%) 121  13.0 108  14.7* 112  18.2 108  15.0 0.060/0.86
DLco/VA (%) 133  19.8 110  27.0* 136  21.7 134  22.4 0.64/<0.0001
PaO2 (torr) 78.0  6.0 79.7  5.9 79.8  6.2 80.4  8.0 0.34/0.62
PaCO2 (torr) 40.9  3.2 40.3  3.3 41.6  4.6 41.1  3.0 0.58/0.25
6-MW test
6-MW distance (m) 555  77 573  71 560  75 579  60 0.80/0.67
6-MW (max PR-rest
PR) (/min)
48.5  18 40.5  13* 44.0  13 38.0  12 0.37/0.34
Borg scale after 6-MW 1.0  1.8 0.57  1.3* 0.5  1.1 0.22  0.77 0.36/0.11
Saturation difference 3.21  2.8 2.62  2.0* 2.1  2.2 2.0  1.7 0.15/0.11
no, number; HRCT, high-resolution computed tomography; M, male; F, female; BMI, body mass index; KL-6, Klebs von der Lungen-6; SP-
A, surfactant protein-A; SP-D, surfactant protein-D; VC, vital capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s;
DLco, diffusing capacity for carbon monoxide; VA, alveolar volume; FRC, functional residual capacity; 6-MW, 6 min walk test; PR, pulse
rate; Saturation difference was calculated by rest SpO2-lowest SpO2 during 6 MW.
*, p < 0.05 abnormal HRCT smoker vs abnormal HRCT non-smoker; Respiratory symptoms include in chronic cough, sputum and shortness
of breath.
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characteristics from the other patterns
As shown in Table 3, the frequency of smokers demon-
strating GGO, honeycombing and CPFE was significantly
higher than of the frequency of the other twopatterns
(p Z 0.009). Five subjects (14%) with a 35 IST pattern in
HRCT scans had lesions of more than 5% in extent, while 5
subjects with honeycombing (71%) and 3 with CPFE (21%)
had lesions >5% in lung extent. Six smoking subjects with
GGO showed CT findings such as respiratory bronchiolitis-
ILD (RB-ILD). The FEV1/FVC and DLco/VA revealed signifi-
cantly lower levels in the CPFE subjects in comparison to
the other HRCT patterns. In addition, no significant differ-
ences were observed in the laboratory data or the 6-min
walk test findings among the subjects of the different HRCT
patterns.
Current smokers in abnormal HRCT smokers
progressed CT score
Seventy-three subjects were followed-up with a CT scan in
periods for at least 4 years. Finally, 4 patients with a hon-
eycombing pattern on the initial HRCT scan showeda typical UIP pattern. During the 4-year period following
the first diagnosis, 1 subject with a UIP pattern on the chest
HRCT had died due to respiratory failure. This patient’s CT
score progressed from 12 to 22. The other three patients
had no treatment, and are now under observation. One
female non-smoking subject required treatment consisting
of prednisolone administration. Four of the 7 abnormal
HRCT current smokers without any symptoms showed
a progression of their CT scores based on the CT findings
and chronic cough and sputum during the follow-up exam-
ination. However, seven abnormal HRCT ex-smoking
subjects did not develop any symptomatic disease. In the
follow-up study, the CT scores of current, former, never,
and current smokers to former smokers were 3.0  1.6,
3.0  1.7, 3.2  2.7 and 2.3  2.4 to 4.0  2.3, 3.3  2.3,
4.4  5.1 and 2.3  2.5, respectively (p Z 0.046, 0.43,
0.65, and 0.99, respectively).
As shown in Table 4, 32 subjects progressed from 3.2 to
5.5 in the CT score (progression group), and 12 improved
from 3.5 to 2.2 (improvement group). Twenty-nine subjects
had no interval changes in the CT score (no interval
change). Current smokers had a significant progression in
their CT score 4 years later in comparison to either never or
former smokers (p Z 0.010). The subjects with abnormal
serum KL-6 and SP-A levels were included in the progressive
Table 3 Clinical data of abnormal HRCT subjects classified by HRCT finding.
HRCT findings
(n)
IST
(35)
IDS
(15)
GGO
(9)
Honeycombing
(7)
CPFE
(14)
Age (years) 61.5  9.5 63.6  8.5 58.9  11.6 61.7  7.3 62.4  10.1
Sex, M/F 21/14 11/4 6/3 7/0 14/0
Current smoker (%) 13 (37.1) 3 (20.0) 5 (55.6) 5 (71.4) 10 (71.4)
Never smoker (%) 14 (40.0) 7 (46.7) 2 (22.2) 0 (0) 1 (7.1)
Cough and/or sputum (%) 18 (51.4) 10 (66.7) 5 (55.6) 3 (42.9) 10 (71.4)
Shortness of breath (%) 6 (17.1) 0 (0) 0 (0) 2 (28.6) 4 (28.6)
Abnormal level of KL-6 (n) 5 3 2 4 2
Serum KL-6 level (U/ml) 385  418 471  591 361  238 378  138 604  1118
Abnormal level of SP-A (n) 21 8 7 5 10
Serum SP-A level (ng/ml) 50.8  17 44.7  14 49.5  23 67.4  36 63.7  30
Abnormal level of SP-D (n) 5 6 2 2 3
Serum SP-D level (ng/ml) 69.4  61 86.8  71 76.1  35 123  81 80.5  48
Pulmonary function test
VC predicted (%) 113  13.0 115  18.1 114  8.7 110  17.8 117  14.3
FEV1/FVC (%) 81.1  7.5 80.8  4.3 79.5  6.7 83.6  6.0 68.8  11.2
FEV1 predicted (%) 113  13.2 117  16.8 112  20.2 113  11.4 104  16.3
%DLco (%) 121  27.6 124  26.9 109  22.8 110  18.6 102  30.7
DLco/VA (%) 124  20.6 129  31.0 116  28.3 113  13.6 88.7  23.1
PaO2 (torr) 81.2  8.8 81.0  4.6 80.0  7.1 80.1  6.2 77.2  7.5
6-MW test
6-MW distance (m) 559  78 559  90 575  40 557  53 595  63
6-MW (max PR-rest PR) (/min) 45.9  15 38.7  10 47.3  18 42.0  14 38.6  18
Borg scale after 6-MW 0.5  1.2 0.4  1.1 0.4  1.3 0.6  1.0 1.7  2.1
Saturation difference 2.5  1.4 3.0  3.7 2.4  1.4 2.2  1.1 3.9  2.6
n, number; IDS; ill-defined subpleural line, IST; interlobular septal thickening, GGO; ground glass opacity, CPFE; combined pulmonary
fibrosis and emphysema; HRCT, high-resolution computed tomography; M, male; F, female; KL-6, Klebs von der Lungen-6; SP-A,
surfactant protein-A; SP-D, surfactant protein-D; VC, vital capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s;
DLco, diffusing capacity for carbon monoxide; 6-MW, 6 min walking test; PR, pulse rate; Saturation difference was calculated by rest
SpO2-lowest SpO2 during 6 MW.
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progression group were higher than that of no interval
change group, and serum SP-D levels in the progression
group were higher than those in the improvement group
(p Z 0.016). One GGO, 1 CPFE, and 2 honeycombing
subjects with an abnormal level of serum KL-6 and 1 GGO, 1
CPFE, and 4 honeycombing subjects with an abnormal level
of serum SP-D were identified in the progression group.
Furthermore, in the progression group, the sensitivity and
specificity of the combination between KL-6 and/or SP-A
were 87% and 46%, SP-A and/or SP-D were 47% and 36%, and
KL-6 and/or SP-D were 83% and 44%, respectively. A
significant correlation was observed between the serum KL-
6 and SP-D levels and the differences in the CT scores,
respectively (rZ 0.27, pZ 0.023, and rZ 0.5, p < 0.0001,
respectively).
Smokers with IDS, GGO, honeycombing, and CPFE
patterns showed the progression of CT scores
As shown in Table 5, six subjects with IST, 9 IDS, 5 GGO, 7
honeycombing, and 5 CPFE were present in the progression
group. Among the 32 subjects with a progression group,
each abnormal lesion developed on the lesions around IST,
honeycombing, and CPFE lesions on the initial HRCT scan,
and the GGO and IDS lesions had expanded around theoriginal lesions as identified in a follow-up study. In addi-
tion, interstitial changes, not emphysematous changes,
progressed in CPFE subjects. The current smokers with IDS,
GGO, honeycombing, and CPFE demonstrated an increased
CT scores in comparison to their initial CT scores. There was
no significant difference in the initial CT scores and the
followed-up CT scores among each HRCT pattern. The CT
scores showed no interval changes in 5 current smokers,
and 1 subject with GGO had no interstitial changes after
smoking cessation. Current smokers in each pattern on
a chest HRCT scan are included in the progression group.Discussion
A major objective of the current study was to clarify the
radiological features of the interstitial change at an early
phase and the association between smoking and radiolog-
ical interstitial changes based on a follow-up study over a 4-
year period. The most frequent abnormality was an IST
pattern, and the majority of the subjects demonstrated
abnormal lesions less than 5% of the total lung. Both hon-
eycombing and CPFE lesions tended to be observed less
frequently, but these patterns included a significant
number of male smokers and a progression of CT scores in
the follow-up studies. There is little information thus far
concerning the IST and IDS patterns.
Table 4 Follow-up over a 4-year period in abnormal HRCT subjects.
CT score
(no.)
(A) Progression
(32)
(B) No interval change
(29)
(C) Improvement
(12)
Age (years) 63.3  110.3* 62.4  8.2* 56.3  6.5
Sex, M/F 26/6 21/8 7/5
Initial CT score 3.2  2.3 2.4  1.7 3.5  1.6
Followed-up CT score 5.5  3.7*# 2.4  1.7 2.2  1.4
Current smoker 18 6 5
Current smoker to former
smoker
1 6 1
Former smoker 6 8 1
Never smoker 7 9 5
Abnormal level of serum KL-6 12*# 3 1
Serum KL-6 level (U/ml) 661  901 322  193 276  119
Abnormal level of serum SP-D 11 6 1
Serum SP-D level (ng/ml) 98.6  69 81.6  50 41.6  36
Abnormal level of serum SP-A 25# 13 8
Serum SP-A level (ng/ml) 57.0  22 52.7  25 47.9  16
Pulmonary function tests
VC predicted (%) 111  14.0# 120  12.4* 111  16.4
FEV1/FVC (%) 79.5  7.5 77.0  11.6 79.6  6.3
FEV1 predicted (%) 113  13.5 114  17.9 103  13.0
DLco/VA (%) 113  27.1 116  26.5 123  25.4
no, number; HRCT, high-resolution computed tomography; M, male; F, female; KL-6, Klebs von der Lungen-6; SP-A, surfactant protein-A;
SP-D, surfactant protein-D; VC, vital capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; DLco, diffusing capacity
for carbon monoxide; VA, alveolar volume; *p < 0.05 compared to improvement; #p < 0.05 compared to no interval change.
Figure 3 The baseline concentration of serum KL-6, SP-A, and SP-D in subjects with abnormal HRCT findings over a 4-year period.
The plots show all data points that lie outside the 5th and 95th percentiles as symbols. (A) The serum KL-6 levels in the progression
group were significantly higher in comparison to those in the improvement and no interval change groups, respectively (pZ 0.049,
and pZ 0.043). (B) No significant differences were observed in the serum SP-A levels among the improvement, no interval change,
and progression groups. (C) The serum SP-D levels in the improvement group were significantly lower in comparison to those in the
no interval change and progression groups, respectively (p Z 0.017, and p Z 0.016).
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Table 5 Follow-up over a 4-year period on each HRCT pattern.
HRCT findings IST IDS GGO Honeycombing CPFE
Smoking history 4 years later
Current smoker 9 2 4 5 9
Current smoker to former
smoker
4 1 1 0 1
Former smoker 3 5 2 2 3
Never smoker 13 6 2 0 1
Initial CT score 2.7  1.6 2.8  1.4 2.6  1.4 5.7  5.5 2.6  2.1
Followed-up CT score 2.7  1.9 3.8  1.9 3.2  2.0 8.9  6.1 3.2  2.4
Progression 6 (4/0/2) 9 (2/4/3) 5 (4/1/0) 7 (5/2/0) 5 (5/0/0)
No interval change 14 (0/1/9) 4 (0/1/2) 2 (0/1/1) 0 (0) 9 (4/3/1)
Improvement 9 (5/2/2) 1 (0/0/1) 2 (0/0/1) 0 (0) 0 (0)
n, number; IDS; ill-defined subpleural line, IST; interlobular septal thickening, GGO; ground glass opacity, CPFE; combined pulmonary
fibrosis and emphysema; HRCT, high-resolution computed tomography; M, male; F, female; KL-6, Klebs von der Lungen-6; SP-A,
surfactant protein-A; SP-D, surfactant protein-D; VC, vital capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s;
DLco, diffusing capacity for carbon monoxide; 6-MW, 6 min walking test; PR, pulse rate; Saturation difference was calculated by rest
SpO2-lowest SpO2 during 6 MW.
(), number of current smoker/former smoker/never smoker.
1720 K. Tsushima et al.A significant age difference was found between subjects
with normal HRCT findings and those with abnormal HRCT
findings. The smoking history of the abnormal HRCT
subjects was consistent with the findings of a prior report.19
Although these populations included healthy subjects and/
or healthy smokers, these age differences suggest that
a progression of interstitial changes may develop within
a period of several years. As shown in Table 4, 32 subjects
with abnormal HRCT findings revealed a progressing CT
score over a period of 4 years. Previous reports have sug-
gested that smoking is associated with the development of
early ILD in subjects with familial interstitial pneu-
monia.11,20 After counselling such patients about quitting
smoking, 8 abnormal HRCT smokers successfully stopped
smoking. Six of these 8 subjects showed no interval changes
in their CT score over a period of 4 years. Eighteen smokers
of 32 abnormal HRCT subjects, including 5 subjects with
honeycombing, demonstrated progressive CT scores over
a 4-year period. Although the number of individuals who
stopped smoking was small, such a cessation of smoking
nevertheless appeared to suppress the progression of
interstitial changes.
The serum KL-6 and SP-A levels are correlated with the
activity of interstitial pneumonia.21,22 As shown in the
current report, the serum SP-A level correlated with the
subject’s pack-year smoking history. The serum SP-A levels
were sensitive in the detection of interstitial change at an
early phase because of a high degree of sensitivity. The
frequency of abnormal serum KL-6 levels in the progression
group was higher than those in the other groups. The serum
SP-D levels in the progression group were significantly higher
in comparison to the improvement group. The GGO, honey-
combing, and CPFE patterns with abnormal levels of serum
KL-6 or SP-D showed a progression of the CT scores. In addi-
tion, a significant correlation was observed between the
serum KL-6, serum SP-D, and the differences of CT scores,
respectively. We suppose that the subjects with abnormal
levels of both serum KL-6 and SP-D could be regarded as
having a greater potential to develop interstitial changes.
These findings therefore suggest that current smokers withabnormal serum KL-6 and SP-D levels and either honey-
combing or CPFE pattern might therefore have a greater
potential to develop interstitial change. Moreover, the
markers of either the serumKL-6or SP-D levelsmaybeable to
predict the progression of interstitial changes.
The current study included subjects with reversible
interstitial changes in their natural clinical course, which
might occasionally be overlooked, and minor CT abnor-
malities, such as IST, IDS, and GGO patterns. However, 6
subjects with IST, including 4 smokers, showed a progres-
sion of their CT scores in the CT findings, and these changes
tended to be small. As shown in Table 4, 12 subjects with
interstitial changes had reversible lesions. Some subjects
with IST and GGO on the chest HRCT scans were considered
to potentially possess reversible lesions after smoking
cessation. Twenty-nine subjects showed no interval
changes in the CT scores. These subjects, especially
smokers, may therefore need to be followed over a period
of several additional years or decades to determine
whether subjects with interstitial changes actually later
develop interstitial changes.
In the analysis of early ILD in patients with familial
pulmonary fibrosis, lung biopsies performed in subjects
with asymptomatic ILD revealed diverse histological
subtypes, including hypersensitivity pneumonia, NSIP, and
cellular interstitial and organizing pneumonia, although
these familial IPF patients with asymptomatic ILD have
a high potential to develop IPF in the future.13 A limitation
of this study is that no precise histologic examinations of
interstitial changes detected by an HRCT scan could be
conducted. A surgical lung biopsy provides samples that
can be used to distinguish IPF from other forms of idio-
pathic interstitial pneumonia of unknown etiology. The
recommendation of a surgical biopsy is important for any
patient with clinical or radiologic features that are not
typical of IPF. The ATS/ERS Consensus committees do not
recommend these invasive procedures for subjects with
mild interstitial changes.23 Moreover, there is still no
consensus regarding the optimal therapy for subjects with
mild interstitial changes. Indeed, no invasive procedures,
The radiological patterns of interstitial change 1721such as bronchoscopy and open lung biopsy, were per-
formed in the abnormal HRCT subjects without respiratory
symptoms or with only mild interstitial changes on the
HRCT scan.
In summary, it is important to categorize the patterns of
CT abnormalities, while carefully taking the patterns and
extent of the lesions into account. The serum SP-A levels
are therefore considered to be good markers to detect
interstitial changes at an early phase, and the serum KL-6
and SP-D levels may predict the progression of early phase
interstitial change based on the CT patterns. Smoking may
be a risk factor for the development of disease. Overall, the
early identification of interstitial change patterns in
smokers with abnormal HRCT findings may improve the
clinical outcome by counselling patients for cessation of
smoking.
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